A Phase 2b, randomised, double blind, placebo controlled, parallel-group, multicentre protocol to evaluate the safety and efficacy of JNJ-64304500 in subjects with moderately to severely active Crohn's disease. (TRIDENT)
1st January 2017 - ongoing
Status: In Recruitment
Specialism: Lower GI.
Novel drug versus placebo study to evaluate the safety and efficacy of high dose JNJ-64304500 in subjects with moderately to severely active Crohn’s disease who have failed biologic or conventional therapy.
|Dr Gordon Moran||Dr Moran did his undergraduate medical training at University of Malta Medical School and was awarded an MD in 1999. He completed his basic postgraduate training at St. Luke's Hospital in Malta and gained membership of the Royal College of Physicians of…|
|Dr Sunil Samuel|